US · EXOZ
eXoZymes, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Monrovia, NV 91016
- Website
- exozymes.com
Price · as of 2024-12-31
$9.75
Market cap 74.23M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | $14.48 |
AI valuation
Our deep-learning model estimates eXoZymes, Inc.'s (EXOZ) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $9.75
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EXOZ | eXoZymes, Inc. | $9.75 | 74.23M | — | — | — | — | -20.08 | 11.29 | — | -19.55 | -10.68 | 11.29 | 0.00% | — | — | -116.80% | -365.14% | -70.65% | 0.13 | — | 8.12 | 7.84 | 1.49 | 18800.00% | — | 50576.00% | -7.56% | -6.38 | -547.95% | 0.00% | 0.00% | 8.39% | -18.43 | -12.28 | — | 25.10 |
| ANEB | Anebulo Pharmaceuticals, … | $0.36 | 14.68M | — | — | — | — | -9.49 | 6.90 | — | -8.50 | — | 6.90 | 0.00% | — | — | -109.69% | -2464.82% | -104.63% | 0.00 | -24.14 | 53.36 | 52.20 | 1.44 | -2188.00% | — | -2152.00% | -7.89% | -28.32 | -1696.85% | 0.00% | 0.00% | 10.60% | -7.47 | -10.85 | — | 89.17 |
| ATOS | Atossa Therapeutics, Inc. | $4.43 | 38.15M | — | — | — | — | -3.65 | 1.30 | — | -0.80 | — | 1.30 | 0.00% | — | — | -31.39% | -1873.25% | -29.54% | 0.00 | — | 14.99 | 14.31 | 2.58 | -1667.00% | — | 45.00% | -22.60% | -4.23 | -1427.53% | 0.00% | 0.00% | 0.00% | -0.80 | -1.05 | — | 7.27 |
| CGTX | Cognition Therapeutics, I… | $1.09 | 80.2M | — | — | — | — | -0.50 | 0.91 | — | 0.21 | — | 0.91 | 0.00% | — | — | -157.19% | 1117.89% | -103.89% | 0.04 | -2158.64 | 2.65 | 2.49 | 0.72 | -116.00% | — | 7617.00% | -167.08% | -2.56 | 589.91% | 0.00% | 0.00% | 0.00% | 0.13 | 0.25 | — | -12.38 |
| ESLA | Estrella Immunopharma, In… | $1.22 | 51.28M | — | — | — | — | -4.10 | 252.14 | — | -3.99 | — | 252.14 | 0.00% | — | — | — | — | — | 0.00 | — | 0.55 | 0.31 | 0.10 | — | — | — | -21.08% | -2.55 | — | 0.00% | 0.00% | 1.57% | -3.99 | -4.62 | — | -13.22 |
| GLSI | Greenwich LifeSciences, I… | $27.72 | 384.05M | — | — | — | — | -9.97 | 62.14 | — | -9.72 | -13.23 | 62.19 | 0.00% | — | — | -341.95% | 1733.85% | -284.78% | 0.00 | — | 2.62 | 2.62 | 0.26 | 7536.00% | — | 1216.00% | -4.61% | -4.66 | 786.86% | 0.00% | 0.00% | 0.00% | -9.58 | -21.11 | — | 25.79 |
| ONCY | Oncolytics Biotech Inc. | $1.13 | 113.41M | — | — | — | — | -2.33 | 12.32 | — | -1.69 | — | 12.32 | 0.00% | — | — | -189.05% | 442.22% | -107.48% | 0.18 | — | 2.82 | 2.39 | 0.43 | 0.00% | — | -440.00% | -36.90% | -4.03 | 343.91% | 0.00% | 0.00% | 0.00% | -1.68 | -2.16 | — | -35.01 |
| SRZN | Surrozen, Inc. | $27.80 | 238.29M | — | -83% | — | — | -0.55 | -1.64 | 3.28 | -0.37 | -34.54 | -1.64 | 100.00% | -239.69% | -596.56% | -767.91% | 121.02% | -134.46% | -0.40 | — | 5.32 | 5.07 | 1.08 | 159.00% | — | -5669.00% | -50.45% | -2.41 | 83.66% | 0.00% | 0.00% | 0.00% | -0.35 | -0.50 | 0.84 | -8.68 |
| TIL | Instil Bio, Inc. | $8.90 | 60.36M | — | — | — | — | -1.61 | 0.70 | — | -1.48 | — | 0.70 | 0.00% | — | — | -37.51% | -48.30% | -25.16% | 0.51 | -8.18 | 15.76 | 14.35 | -1.25 | -5254.00% | — | -3603.00% | -55.11% | -7.05 | -43.15% | 0.00% | 0.00% | 0.00% | -1.26 | -1.41 | — | -3.11 |
| TLSA | Tiziana Life Sciences Ltd | $1.45 | 86.17M | — | — | — | — | -9.51 | 22.90 | — | -5.21 | — | 22.90 | 0.00% | — | — | -200.16% | -455.01% | -80.79% | 0.03 | -2632.33 | 1.02 | 1.01 | 0.22 | -3529.00% | — | -9006.00% | -1.37% | -0.17 | -50.21% | 0.00% | 0.00% | 2.98% | -5.48 | -70.08 | — | -15.21 |
| TVGN | Tevogen Bio Holdings Inc. | $0.26 | 53.24M | — | — | — | — | -12.18 | -25.05 | — | -12.85 | -0.05 | -25.05 | 0.00% | — | — | 27.16% | 2087.12% | -306.17% | -0.43 | -291.05 | 0.26 | 0.16 | -0.12 | 2330000.00% | — | 4449.00% | -7.18% | -1.33 | 467.53% | 0.00% | 0.00% | 55.48% | -3.15 | -14.07 | — | -89.34 |
About eXoZymes, Inc.
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
- CEO
- Michael Heltzen
- Employees
- 31
- Beta
- 2.55
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $9.75) − 1 = — (DCF, example).